首页> 外文会议>European Control Conference >Bihormonal glucose control using a continuous insulin pump and a glucagon-pen
【24h】

Bihormonal glucose control using a continuous insulin pump and a glucagon-pen

机译:使用连续胰岛素泵和胰高血糖素笔控制双激素葡萄糖

获取原文

摘要

The combined use of insulin and glucagon in the diabetes therapy has been proposed as a robust alternative to the classical insulin only approach relieving the patient of the psychological burden related to the risk of falling into hypoglycemia. The standard setup usually considered is based on two pumps controlled manually or, in future, automatically. While the results so far are very promising, the device complexity represents a serious disadvantage. Against this background, this paper examines the possibility to use a pump for insulin, but only a pen for glucagon, which becomes so in some way a safety net, used only occasionally. This paper uses an existing simulation model for the human glucoregulatory system to develop a model predictive controller for this setup and analyzed the effect of errors in the carbohydrate (CHO) estimations for the meal announcements, the most common cause of hypoglycemia. In-silico tests using the simulation model and data of two patients allow a proof of concept, showing that the risk of hypoglycemia can be removed and the glucagon pen injection becomes necessary only if the overestimation is sufficiently large. The amount of infused insulin and the time spent in hyperglycemia is hardly affected by these glucagon injections, but a higher or earlier insulin delivery is possible and increases the time in the euglycemic range. Thus the proposed method can retain most advantages of the dual pump approach while being more patient friendly. It is expected to encourage diabetics to target a better BG level without the usual safety margin as the glucagon availability takes over this safety function.
机译:胰岛素和胰高血糖素在糖尿病疗法中的结合使用是一种稳健的替代型胰岛素,仅对与落入低血糖症的风险有关的心理负担的患者。通常考虑的标准设置基于手动控制的两个泵,或者将来自动控制。虽然到目前为止的结果非常有前途,但设备复杂性代表着严重的缺点。在此背景下,本文审查了使用胰岛素使用泵的可能性,但只有一支胰岛素,这在某种程度上是一种安全网,仅偶尔使用。本文对人筋系统的现有仿真模型开发了该设置的模型预测控制器,并分析了碳水化合物(CHO)估算中的误差的效果,为膳食公告,低血糖最常见的原因。使用仿真模型和两个患者的硅测试允许概念证明,表明可以去除低血糖的风险,只有在高估足够大时才需要胰高血糖素笔注射。注入的胰岛素的量和高血糖症所花费的时间几乎不会受到这些胰高血糖素注射的影响,但是可能的胰岛素递送更高或更早的胰岛素递送,并增加了外血糖范围内的时间。因此,所提出的方法可以在更耐心友好的同时保持双泵方法的大部分优势。预计糖尿病患者可以在没有通常的安全范围内瞄准更好的BG水平,因为胰高血糖素可用性接管了这种安全功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号